According to Zacks, “Stryker has outperformed the industry in a year. The company continues to gain from its core MedSurg unit which put up a solid show in recent times. Additionally, strength in flagship Mako platform has consistently favored the company. Management is optimistic about the recent K2M acquisition which drove the core Neurotechnology & Spine unit in recent times. Solid international growth also buoys optimism. Expansion in operating margin is a positive while a strong view for 2019 is indicative of brighter prospects ahead. On the flip side, contraction in gross margin raises concern. Additionally, revenues in the last reported quarter were impacted by unfavorable foreign currency movement. Pricing pressure also continues to plague Stryker. Stiff competition in the MedTech space remains a headwind for the company. The stock is overvalued at the moment.”
A number of other equities analysts have also commented on the company. Wells Fargo & Co increased their price target on Stryker from $214.00 to $219.00 and gave the company an outperform rating in a research note on Monday, April 1st. JPMorgan Chase & Co. increased their price target on Stryker from $200.00 to $215.00 and gave the company an overweight rating in a research note on Tuesday, March 19th. BTIG Research increased their price target on Stryker to $211.00 and gave the company a buy rating in a research note on Monday, March 18th. Royal Bank of Canada raised their price objective on Stryker from $184.00 to $204.00 and gave the company an outperform rating in a research note on Monday, March 11th. Finally, Barclays set a $203.00 price objective on Stryker and gave the company a buy rating in a research note on Friday, March 8th. Eight analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $192.13.
Shares of Stryker stock opened at $193.42 on Friday. Stryker has a 12 month low of $144.75 and a 12 month high of $199.85. The company has a market cap of $72.88 billion, a P/E ratio of 26.46, a PEG ratio of 2.40 and a beta of 0.88. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.02 and a quick ratio of 1.41.
Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 29th. The medical technology company reported $2.18 EPS for the quarter, beating analysts’ consensus estimates of $2.15 by $0.03. Stryker had a return on equity of 27.60% and a net margin of 26.12%. The company had revenue of $3.80 billion during the quarter, compared to analyst estimates of $3.73 billion. Research analysts predict that Stryker will post 8.13 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 1.08%. The ex-dividend date is Thursday, March 28th. Stryker’s payout ratio is 28.45%.
In other news, Chairman Kevin Lobo sold 41,750 shares of the stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $194.11, for a total value of $8,104,092.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Katherine Ann Owen sold 29,247 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $185.62, for a total value of $5,428,828.14. Following the completion of the sale, the vice president now owns 11,131 shares in the company, valued at $2,066,136.22. The disclosure for this sale can be found here. Insiders sold a total of 131,071 shares of company stock valued at $24,689,161 over the last ninety days. Corporate insiders own 7.20% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of SYK. ERTS Wealth Advisors LLC purchased a new stake in shares of Stryker in the fourth quarter worth approximately $25,000. Northwest Wealth Management LLC increased its holdings in Stryker by 103.6% during the 4th quarter. Northwest Wealth Management LLC now owns 169 shares of the medical technology company’s stock worth $26,000 after purchasing an additional 86 shares during the period. Semmax Financial Advisors Inc. purchased a new position in Stryker during the 4th quarter worth $28,000. Horan Securities Inc. purchased a new position in Stryker during the 4th quarter worth $30,000. Finally, Truehand Inc purchased a new position in Stryker during the 4th quarter worth $30,000. Hedge funds and other institutional investors own 74.58% of the company’s stock.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
See Also: Is the QQQ ETF safe?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.